Unicycive Therapeutics
UNCY
16 hedge funds and large institutions have $11.3M invested in Unicycive Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.33% less ownership
Funds ownership: 4.08% → 3.75% (-0.33%)
7% less capital invested
Capital invested by funds: $12.2M → $11.3M (-$898K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.2K |
| 3 |
Renaissance Technologies
New York
|
+$22.3K |
| 4 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$6.54K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$847K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$21.2K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$10.2K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$9.6K |
| 5 |
VF
Virtu Financial
New York
|
-$9K |
UNCY Hedge Fund Activity: Q4 2023 in Review
16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q4 2023, worth a combined $11.3M — down 7.4% from $12.2M a quarter earlier.
Fund positioning in UNCY was balanced in Q4 2023: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $76.3K. The largest seller was BVF Inc, cutting an estimated $847K.
- 16 institutional investors held Unicycive Therapeutics (UNCY) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $11.3M of Unicycive Therapeutics stock for Q4 2023, down 7.4% quarter-over-quarter.
- 3 funds opened new Unicycive Therapeutics positions in Q4 2023 and 3 closed out, a net change of 0 holders.
- The largest Unicycive Therapeutics buyer in Q4 2023 was Geode Capital Management, an estimated $76.3K added.
- The largest Unicycive Therapeutics seller in Q4 2023 was BVF Inc, an estimated $847K sold.
Based on aggregated 13F filings for Q4 2023.